2016年6月30日 星期四

Managing pain in a patient with pancreatic cancer (2)

pancreatic cancer (2)



Discussion
Pain is one of the most common symptoms experienced by cancer patients. It has been estimated that approximately 50 to 70 percent of patients with cancer experience some degree of pain, which usually progresses and intensifies as the disease progresses.¹ One study noted that the incidence of pain in patients with advanced stages of invasive cancer may be as high as 80 percent. The incidence can be as high as 90 percent for those with metastases in osseous structures.² However, more than half of cancer patients have insufficient pain control. Severe pain can significantly impair patients’ quality of life and interfere with their physical rehabilitation, nutrition and mobility. Furthermore, a large number of cancer patients suffer from depression.³

Several practice guidelines on pain control have been formulated. The most widely used algorithm in the management of cancer pain is probably the one formulated by the WHO, called the WHO cancer pain treatment step ladder. These guidelines recommend the use of paracetamol or NSAIDs as an initial step in pain management, followed by opioid analgesic for mild to moderate pain, and strong opioids for moderate to severe pain. (Figure 2) However, some experts have stated that the WHO guidelines may be inadequate to address current needs and suggested the addition of a fourth interventional step in the form of nerve blocks, intrathecal delivery systems, or surgical procedures.

Oxycodone is a synthetic opioid metabolized to its active metabolite, oxymorphone, in the liver. A comparison of oxycodone CR and morphine demonstrated similar analgesic effects between the two drugs. However, there were significant differences in pain control for patients with underlying renal or hepatic impairment receiving oxyvodone.⁶ although oxycodone is generally more expensive than morphine, it has proven efficacy in treating moderate to severe pain, and its CR formulation allows for the convenience of 12-hour dosing intervals.⁷

The use of opioids, though often perceived to be associated with palliative care, plays and important role in pain management. In the case of our patient, it resulted in satisfactory pain control and improved quality of life, enabling him to undergo and tolerate subsequent chemotherapy, which can potentially control the disease and prolong survival.
Dr Leung-Cho Chan         

                                        
Specialist in Clinical Oncology Private practice Hong Kong


Reference information:  oncologytribune
The information aims to provide educational purpose only. Anyone reading it should consult Oncologist before considering treatment and should not rely on the information above

2016年6月29日 星期三

Managing pain in a patient with pancreatic cancer (1)

Presentation and management
This is the case of a 53-year-old married male with children who sought consultation for progressive abdominal pain in April 2014. The pain had been present for 1 to 2 months prior to the consultation, and was previously diagnosed by other doctors as pain due to gastritis. 

The patient described the pain as severe, giving it a score of 7 to 8 on a numerical rating scale of 1 to 10. Esophagogastroduodenoscopy was unremarkable, but CT scan revealed a pancreatic tumor with liver metastasis and mild ascites, which was inoperable due to celiac plexus infiltration and secondary lesions in the liver. Pain management was initiated using oxycodone 10 mg controlled-release (CR) tablets twice daily and oxycodone 5 mg capsules as needed. 

The patient was informed of possible side effects such as dizziness, nausea, vomiting and constipation. Metoclopramide and a senna-based laxative were prescribed for nausea and vomiting, and constipation, respectively.
The patient then underwent intensity-modulated radiotherapy, receiving 3.0 Gy per fraction at the tumor area, 2.8 Gy at the 0.7 cm tumor margin, and 2.5 Gy at the 1.0 cm tumor margin for a total of 15 fractions given over 3 weeks. (Figure 1)
Pain intensity improved from a score of 7 to 8 initial consultation to 4 after 3 to 4 days of treatment with oxycodone. Two weeks after radiotherapy, pain intensity further reduced to a score of 2. The dose of oxycodone was reduced to one 10 mg CR tablet daily at night time. Oxycodone 5 mg capsule was discontinued and replaced by an NSAID taken as needed during daytime.
During follow-up visits every 1 to 2 months, the patient reported only mild pain. He is now receiving gemcitabine as single-agent chemotherapy at a public hospital.

Dr Leung-Cho Chan                                                 
Specialist in Clinical Oncology Private practice Hong Kong





Reference information:  oncologytribune
The information aims to provide educational purpose only. Anyone reading it should consult Oncologist before considering treatment and should not rely on the information above.

2016年6月21日 星期二

卵巢癌病徵不明顯,標靶藥物配合化療抗癌魔 (下)




標靶藥物也可治療子宮頸癌
由此可見,現時卵巢癌的治療有不少進步,陳亮祖醫生建議卵巢癌患者確診後,應與醫生積極商討,尋找適合及有效的治療方案。事實上,抗血管增生的標靶藥物的應用越來越廣泛,除了卵巢癌,子宮頸癌也成為另一種可使用標靶藥物來提高治療效果的婦科癌症,臨床研究顯示,子宮頸癌患者接受抗血管增生標靶藥物配合化療的治療後,存活期中位數增加至17 個月,明顯較只使用化療為長,為患者增加存活機會。


卵巢癌的高危因素及病徵
高危因素

•    從未生育
•    從未哺乳
•    有家族病史
•    帶有遺傳基因,如BRCA1, BRCA2
•    肥胖

病徵
•    腹部或骨盆疼痛
•    便秘
•    腹瀉
•    小便頻密
•    陰道出血
•    腹脹
•    乏力

 

擴散至肝臟的卵巢癌
五十多歲的張女士(化名)因腹脹求醫,結果證實患上卵巢癌。手術雖然能夠完成切除位於盆腔的腫瘤,可是正電子掃描發現在她的肝臟有3粒腫瘤。經過與醫生商討後,張女士接受化療配合抗血管增生的標靶藥物。經過約3個月四次化療後,醫生再替張女士安排正電子掃描檢查,已發現她肝臟的腫瘤已經消失,再完成剩下的兩個周期治療後,她現在接受單獨標靶藥物的治療,以鞏固療效。


臨床腫瘤科專科醫生陳亮祖醫生





參考資料:  Wen Wei Po
以上所提供的資訊僅作為教育及參考用途,如果你有任何醫療問題,
應向自己的腫瘤科專科醫生查詢,而不應單倚賴以上提供的資料。

2016年6月20日 星期一

卵巢癌病徵不明顯,標靶藥物配合化療抗癌魔 (上)

據資料顯示,香港每年分別有五百多宗卵巢癌新症及二百多宗卵巢癌死亡個案。中國內地於2015年更估計有五萬二千宗新增的卵巢癌個案,而死亡個案更高達二萬二千宗,可見卵巢癌對華人女性構成不可忽視的健康威脅。近年卵巢癌的治療選擇新增了標靶藥物,以幫助提高治療效果,讓患者及醫生擁有更多武器對抗癌魔。

卵巢癌沒有特別病徵

卵巢癌是一種不容易被察覺的癌症。臨床腫瘤科專科醫生陳亮祖醫生指出:「卵巢位於盆腔深處,即使長出腫瘤也不容易產生明顯病徵;此外,卵巢雖然是女性生殖器官之一,但卵巢癌並不似其他婦科癌症般容易造成下體出血,反而,它所帶來的下腹痛與腸胃不適或經痛相似,容易被患者忽略。故此,當下腹不適持續兩星期,應找醫生進行檢查。」

儘管卵巢癌的病徵並不明顯,不過透過盆腔超聲波檢查,可清楚分辨卵巢囊腫的屬性—倘若囊腫屬清澈透明則多為良性,實心硬塊則屬惡性機會較大。

卵巢癌的主要治療方案是手術切除,醫生會為患者切除盆腔的腫瘤,即使未能完全移除,但如果能夠把腫瘤的直徑盡量減至5毫米以下,也對病情有莫大幫助。陳亮祖醫生指出,若醫生判斷腫瘤範圍過大,未能第一時間做理想清除手術(即殘餘腫瘤小於1厘米),可先進行化療縮小腫瘤,再進行手術。至於第四期,即出現肝臟、肺部等轉移,需要接受化療,以改善病情。

抑制腫瘤血管標靶藥物提高治療效果
近年,抗血管增生的標靶藥物開始被廣泛用於治療晚期卵巢癌,當它與化療一併使用時,可進一步提高病情的控制。研究發現,該標靶藥物與化療一併使用比單用化療更能延長對病情的控制,而且對於高危患者(完成手術後剩餘腫瘤大於1cm的患者)來說,加入標靶治療更可延長存活時間至39.7個月,較單獨使用化療的30.2個月長。陳亮祖醫生補充,有鑑於卵巢癌的惡性不低,所以高危患者於完成數個月的化療合併標靶藥物的治療後,仍需接受為期12個療程的單獨標靶藥物治療,才能把治療效果發揮至最好。

此外,卵巢癌的復發率不低,約有五成第三期卵巢癌患者會在身體其他部位出現復發腫瘤。陳亮祖醫生表示,以手術切除腫瘤仍然是復發個案最理想的治療方法,但是大部份患者未必適合再次進行手術,她們需要以化療來控制病情,現在她們還可選擇在化療之上加入標靶治療來提升療效。根據臨床研究顯示,加入標靶藥物可以提高反應率一倍以上,協助患者延遲病情惡化。

.......續


















參考資料:  Wen Wei Po
以上所提供的資訊僅作為教育及參考用途,如果你有任何醫療問題,
應向自己的腫瘤科專科醫生查詢,而不應單倚賴以上提供的資料。

2016年6月16日 星期四

晚期腸癌 標靶藥延壽

大腸癌近年再次超越肺癌,成為本港「頭號癌症」,由於初期症狀不明顯,不少患者病發時已屬晚期。不過,末期不等如末路。晚期患者仍能透過化療配合標靶藥治療,令腫瘤縮小,延緩病情惡化。新一代標靶藥更能有效抑制癌細胞生長,晚期患者雖無法以手術根治癌症,卻能透過藥物延長壽命。


腸癌標靶藥主要分針對表皮生長因子和血管生長因子兩種。只有約四成病人適合使用抑制表皮生長因子的標靶藥,而抑制血管生長的標靶藥則大部分患者適用。第一代抑制血管增生標靶藥只能對抗一種血管新生因子,但新一代卻能對抗3種,因此可更有效抑制腫瘤生長。臨牀結果顯示,相對於單用化學治療,晚期腸癌患者在接受Aflibercept配合化療後,整體存活期由平均12.06個月增加至13.5個月;疾病控制時間也延長2.5個月,整體死亡風險更降低兩成。新藥的常見副作用有高血壓,罕有的副作用包括增加心血管疾病和穿腸的風險,但較傳統化療藥物引發的副作用少。

末期患者只要堅持接受治療,存活時間可大大延長。當然,腸壁瘜肉演變成惡性腫瘤要好幾年,高危一族應及早接受大腸癌篩查。所謂病向淺中醫,早期腸癌的痊愈率高達九成三以上,第三期的五年存活率也有七成,但第四期只剩一成,因此及早發現及治療是最為重要的。


陳亮祖醫生
臨牀腫瘤科專科醫生














參考資料: http://www.metrohk.com.hk/index.php?cmd=detail&id=310667&search=1
以上所提供的資訊僅作為教育及參考用途,如果你有任何醫療問題,
應向自己的腫瘤科專科醫生查詢,而不應單倚賴以上提供的資料。

2016年6月15日 星期三

KRAS是甚麼?

對於第四期大腸癌的病友,醫生會提出做一個名為KRAS基因變異的測試。KRAS到底是甚麼?為甚麼要做這個測試呢?

KRAS是一種原致癌基因(Proto-oncogene),它會製造一個叫RAS的蛋白份子,對細胞的生長、增殖和血管生長等起「開關」的作用。正常的 KRAS基因(即無變異)可抑制腫瘤細胞生長,倘若KRAS基因發生突變(即有變異),它製造出的RAS蛋白會持續刺激細胞生長,打亂生長規律,形成癌 症。

事實上,六成五或以上的胰腺癌,三成六的大腸癌及兩成的非小細胞的肺癌,都跟KRAS基因變異有關。

                                                                                
       
根據○七年臨牀第三期的大型研究,第四期大腸癌病人使用CETUXIMAB(一種標靶藥物),與標準化療FOLFIRI一併使用,若患者的KRAS基因是無變異,能增強化療的功效,一年內腫瘤沒有惡化而繼續存活的機率,幾乎是那些只接受化療者的兩倍。


KRAS基因測試,已是第四期腸癌個人化治療方案中重要一環。在歐美國家,亦成為第四期腸癌患者的標準檢查。

臨牀腫瘤科專科醫生
陳亮祖醫生






參考資料: http://news.stheadline.com/
以上所提供的資訊僅作為教育及參考用途,如果你有任何醫療問題,
應向自己的腫瘤科專科醫生查詢,而不應單倚賴以上提供的資料。

2016年6月9日 星期四

Continuum of care for colorectal cancer: Finding the optimal treatment course (2)








Discussion

The continuum-of-care approach in CRC emphasizes individualized therapy that exposes patient to different combinations of cytotoxic and targeted agents. Physicians can utilize, discontinue, or re-use agents across several lines of treatment, according to factors such as: treatment goals; patient preference; patient’s general condition; disease characteristics; and efficacy and tolerability profiles of the drugs. However, the choice of first-line treatment affects which subsequent treatment options can be used, and physicians often undergo an intensive discussion of benefits and risks with patients and their families before each treatment decision.

Patients with unresectable disease but without other tumour-related symptoms are generally offered a doublet cytotoxic regimen, such as oxaliplatin with a fluoropyrimidine, and a targeted agent, for disease control. Current clinical evidence favours bevacizumab in the first-line setting, but KRAS wild-type tumours may benefit from an anti-epidermal growth factor receptor antibody. Upon progression, oxaliplatin or irinotecan may be offered in a sequential manner, along with a targeted biological agent. As second-line treatment, the clinical benefit of the antiangiogenic agent aflibercept was demonstrated in VELUR, a phase III, randomized, placebo-controlled trial. Aflibercept with 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) significantly improved overall survival (13.50 versus 12.06 months; hazard ratio [HR] 0.817; 95% confidence interval [CI] 0.713-0.937; p<0.0032) and progression-free survival (6.90 vs 4.67 months; HR 0.758; 95% CI 0.661-0.869; p<0.0001) in patients with mCRC previously treated with an oxaliplatin-based regimen, including those who had received bevacizumab. In the present case, the distinct mechanisms of action of irinotecan and aflibercept may have contributed to the patient’s good response. Her regimen appears effective and is also particularly suitable for patients who have a preference for convenient outpatient treatment.





Reference information: www.cancerdoctor.hk
The information aims to provide educational purpose only. Anyone reading it should consult Oncologist before considering treatment and should not rely on the information above.

2016年6月8日 星期三

Continuum of care for colorectal cancer: Finding the optimal treatment course (1)

Introduction

Treatment for advanced colorectal cancer (CRC) has evolved over the years, particularly recently with the addition of novel targeted agents to chemotherapy. There are now several treatment combinations and treatment sequences from which patients can benefit under a continuum of care. This case describes a patient with metastatic CRC (mCRC) who initially received upfront capecitabine-oxaliplatin with bevacizumab. Due to poor disease response, she was switched to another cytotoxic combination with a targeted agent and has demonstrated a response.

Presentation and disease course

The patient is a 63-year-old female, with good functional status, who presented to the clinic in February 2014 with right upper quadrant pain. Upon further investigation, she was found to have stage IV CRC with multiple metastatic liver lesions. The tumour tested positive for KRAS mutation. At the time of diagnosis, the tumour was deemed unsuitable for resection and, consequently, the patient was offered combination cytotoxic chemotherapy with the targeted biological agent bevacizumab. The patient initially requested foregoing bevacizumab treatment to avoid the potential side effect of bleeding. She also requested foregoing a convenient regimen and consequently underwent three cycles of capecitabine with oxaliplatin, or XELOX (capecitabine, 1,400 mg twice a day from days 1 to 14; oxaliplatin, 170 mg given every 3 weeks) as an outpatient.

A follow-up positron emission tomography-computed tomography (PET-CT) scan showed only minimal tumour response (Figure), and her carcinoembryonic antigen (CEA) level had increased from the pretreatment level of 130 ng/mL to 190 ng/mL. The patient agreed to add bevacizumab (350 mg/cycle, given every 3 weeks) to XELOX at the fourth cycle. After a total of six cycles of XELOX, however, only a small decrease in CEA was seen, Second-line treatment options with other chemotherapy combinations were discussed with the patient, and she continued to stipulate a preference for outpatient treatment. From July 2014, the patient received irinotecan (260 mg) with the addition of the targeted agent aflibercept (200 mg/cycle, given every 2 weeks) to optimize tumour response. Capecitabine was not used because she had thrombocytopenia during the XELOX regimen.

The CEA level decreased to 30 ng/mL at the third cycle of second-line therapy, and to 13.3 ng/mL after the sixth cycle. Furthermore, following the sixth cycle, her tumour responded with marked decrease in size and in fluorodeoxyglucose (FDG)uptake of liver lesions (Figure). The patient developed neutropenia (but no fever); otherwise, she tolerated her treatment well. She had earlier received granulocyte colony-stimulating factor (G-CSF) for chemotherapy support.

........cont'










Reference information: www.cancerdoctor.hk
The information aims to provide educational purpose only. Anyone reading it should consult Oncologist before considering treatment and should not rely on the information above.

2016年6月2日 星期四

癌的啟示︰放射治療護理 多認識少恐懼



放射治療(電療)是使用高能量放射線治療癌症的方法。高能量放射線能破壞癌細胞的染色體,使癌細胞死亡。正常細胞的染色體也會受影響,但它有自我修復能力,而癌細胞卻缺乏這能力。


宜花灑浴 水溫忌過熱

若照射部位有紋點或刺繡定位,切勿擦掉或自行加深顏色。如顏色變淡,應立即通知放射治療師。治療進入第二周後,照射部位的皮膚會發紅乾燥, 病人可塗上醫生或護士處方的蘆薈啫喱或水分潤膚霜作護理,治療前以溫水洗掉便可。切勿在照射部位塗抹含果酸及香水等刺激性成分的護膚品。

病人宜選質地柔軟透氣兼剪裁寬鬆的衣物,避免擦損皮膚,女士可穿長袍或鬆身裙。每天以花灑浴代替浸浴,水溫切忌過熱。皮膚要保持乾爽,尤其腋下、腹股溝的皺摺位置。沐浴後以軟毛巾拭乾,忌大力擦皮膚。

若皮膚破損或潰瘍,應告知護士作無菌換症以防感染。放射部位的毛髮會脫落,治療完成後會再生長。外出時,可戴絲巾或打傘遮擋陽光,免紫外線曬傷放射部位的皮膚。電療期間,病人要採取避孕措施,以免對胎兒構成傷害。治療完畢後,上述副作用會漸消退。

病人如欲了解更多放射治療期間的護理,歡迎致電39213777,與本會「癌症家庭支援計劃」的註冊護士、社工詳談。多一分認識,少一分恐懼。服務費用全免。

臨床腫瘤科專科陳亮祖醫生
腫瘤科及紓緩科專科護士朱嘉麗
香港防癌會





參考資料:  http://www.orientaldaily.on.cc/cnt/news/20140403/00176_093.html
以上所提供的資訊僅作為教育及參考用途,如果你有任何醫療問題,
應向自己的腫瘤科專科醫生查詢,而不應單倚賴以上提供的資料。

2016年6月1日 星期三

頭頸癌 Q & A (3)






如何治療?

第一期,可以選擇電療或手術;第二期,以電療為主;第三四期則需要合併治療,手術再加電療。

喉癌手術後,頸部為何留下造口?


喉部的會厭軟骨,負責保護氣道,吞嚥時會關閉,防止食物誤入氣管;但喉癌手術會將會厭軟骨切除,為免病人「吞錯隔」,需要在氣管造口,幫助呼吸。

割走聲帶 借助儀器發聲

割走聲帶,病人會變啞?


手術割走聲帶,病人可以利用人工發聲儀器,說話時把儀器放在頸部造口附近,透過儀器震盪模擬人聲;另外,病人亦可以考慮在喉嚨內植入一片人工瓣膜,每當說話時,用手按造口位置,空氣刺激瓣膜震動,模擬人聲。

選擇電療,可以保住聲帶

對,電療可以保留聲帶。採用新的調強電療,加強腫瘤電療劑量,當腫瘤較大,直接電療,效果未必理想,可先用誘導性的化療針,將腫瘤縮小,再進行電療;另外,晚期喉癌,電療同步化療,加強治療效果,但部分長者若不能承受化療副作用,可以選擇標靶治療結合電療。

喉癌會否擴散至其他器官?

當然有機會,喉癌四期最常見擴散位置是肺部。

喉癌有哪些標靶藥物?是否需要進行基因檢查?


超過九成喉癌,都有EGFR基因突變,可以選擇標靶藥Cetuximab;不過,由於標靶藥療效不及化療,所以多用於第二線治療。

電療疑問

疑問一:鼻咽癌治癒後,病人仍然頭痛、流鼻血,檢查後並沒有復發,原因為何?


這可能是電療後遺症。接受電療後,病人鼻黏膜分泌減少,鼻膜變乾,容易流鼻血,鼻垢亦積在鼻腔,愈積愈厚,引發炎症,像鼻竇炎般出現頭痛不適。解決方法很簡單,病人每天早晚洗鼻,用鼻泵將生理鹽水或涼開水灌入鼻腔,將鼻垢出。

疑問二:喉癌電療有沒有後遺症?


病人完成電療後,電療範圍感到拉緊,聲音有點沙啞,吞嚥有點不暢順;若喉癌屬較後期,電療劑量較高,還可能影響甲狀腺分泌減低,需要服用補充劑;咽喉肌肉協調亦會出問題,容易「吞錯隔」,引起肺炎。





參考資料: 臨床腫瘤科專科醫生陳亮祖醫生
以上所提供的資訊僅作為教育及參考用途,如果你有任何醫療問題,
應向自己的腫瘤科專科醫生查詢,而不應單倚賴以上提供的資料。